🇺🇸 FDA
Pipeline program

Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)

91396

Phase 2 small_molecule completed

Quick answer

Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A) for Magnetic Resonance Angiography is a Phase 2 program (small_molecule) at Bayer HealthCare AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer HealthCare AG
Indication
Magnetic Resonance Angiography
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials